Evidence map›Paper›PMID 42399676›Full record

ArticleOncogene2026

Aberrant splicing in human cancer shows possible functional impact on transcription factors.

Khalique Newaz, Olga Tsoy, Jan Baumbach

Abstract read
In one paragraph

Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Khalique NewazInstitute for Computational Systems Biomedicine, University of Hamburg, Hamburg, Germany. khalique.newaz@uni-hamburg.de.ORCID http://orcid.org/0000-0002-1192-8360
Olga TsoyInstitute for Computational Systems Biomedicine, University of Hamburg, Hamburg, Germany.
Jan BaumbachInstitute for Computational Systems Biomedicine, University of Hamburg, Hamburg, Germany.

Funding

Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research) 01ZX2208ABundesministerium für Bildung und Forschung (Federal Ministry of Education and Research) 031L0287BDeutsche Forschungsgemeinschaft (German Research Foundation) 517063424
6 · The paper itself

Abstract

Cancer shows aberrant alternative splicing (AS), which could functionally perturb proteins required for normal cellular behavior. Transcription factors (TFs) are proteins that regulate gene transcription. Some evidence about AS-driven perturbation of TFs in cancer has been documented. A systematic analysis of how cancer-specific AS could affect structural or functional characteristics of TFs is missing. Such an analysis could reveal the molecular mechanisms of cancer progression due to transcription misregulations, and thus could help identify therapeutic targets. Here, we systematically analyzed AS-induced structural and potential functional perturbations of TFs across 15 cancer types. We identified 2170 perturbed AS events (i.e., events showing significant AS pattern differences between normal and paired cancer samples) that affect 727 TFs across 14 cancer types. In 205 TFs, the perturbed AS events affect known functional domains of TFs. Additional evidence for a potential functional impact of cancer-specific AS on TFs was also found by (1) relating AS patterns of the perturbed AS events with the DNA-binding and regulatory activity of TFs and (2) using cancer dependency data to explore whether the affected TFs are essential for cancer cell line proliferation. Our findings show a large-scale, likely functional, perturbation of TFs due to cancer-specific AS.

Indexed as

Alternative SplicingNeoplasmsTranscription FactorsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansTranscription Factors

Identifiers

PMID42399676
PMCPMC13433238

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.